Literature DB >> 29228725

Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region.

Shuhua Yi1, Yuting Yan1, Wenjie Xiong1, Rui Lv1, Zhen Yu1, Wei Liu1, Enbin Liu1, Heng Li1, Huimin Liu1, Zengjun Li1, Gang An1, Yan Xu1, Kun Ru1, Dehui Zou1, Lugui Qiu1.   

Abstract

Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell neoplasm with hepatitis virus supposed to involve in the pathogenesis. The characteristics of SMZL derived from Caucasia population and high hepatitis C virus (HCV) infection region have been widely investigated, but few was reported in the Eastern population with HBV prevalent region. We analyzed the clinical characteristics, cytogenetic aberrations and prognostic factors in 160 SMZL patients from China. 25 patients (16%) were HBsAg-positive and 54 (34%) patients with resolved HBV infection. IGH gene usage was analyzed in 39 patients. The preferential usages of IGHV genes were IGHV1-2 (26%), followed by IGHV4-34 (18%) and IGHV2-70 (10%). The patients with HBV infection presented biased IGHV-D-J rearrangements and mutational status. Using three independent factors hemoglobin level, HBsAg positivity and complex karyotype, we developed a new hierarchical prognostic model, which showed a better c-index than the previously reported IIL and HPLL scoring systems in SMZL. In conclusion, SMZL in HBV prevalent region have unique clinical and biological characteristics and new prognostic scoring model should be adopted in this population.

Entities:  

Keywords:  IGH gene; cytogenetic aberration; hepatitis B virus (HBV); prognosis; splenic marginal zone lymphoma (SMZL)

Year:  2017        PMID: 29228725      PMCID: PMC5716765          DOI: 10.18632/oncotarget.21931

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  33 in total

1.  Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.

Authors:  Adam J Olszewski
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

2.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

3.  Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.

Authors:  Nilima Parry-Jones; Estella Matutes; Alicja M Gruszka-Westwood; G John Swansbury; Andrew C Wotherspoon; Daniel Catovsky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

4.  Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Evangelia Dimitriadou; Maria K Angelopoulou; Marina P Siakantaris; Marie-Christine Kyrtsonis; Maria Ximeris; Tatiana Tzenou; Sotirios Sahanas; Xanthi Yiakoumis; Eleni A Papadaki; Panayiotis Panayiotidis; Theodoros Vassilakopoulos
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

Review 5.  Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.

Authors:  Catherine Thieblemont; Pascale Felman; Francoise Berger; Charles Dumontet; Philippe Arnaud; Olivier Hequet; Josette Arcache; Evelyne Callet-Bauchu; Gilles Salles; Bertrand Coiffier
Journal:  Clin Lymphoma       Date:  2002-06

6.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos
Journal:  Oncologist       Date:  2013-01-23

7.  Splenic marginal zone lymphoma: a prognostic model for clinical use.

Authors:  Luca Arcaini; Mario Lazzarino; Nora Colombo; Sara Burcheri; Emanuela Boveri; Marco Paulli; Enrica Morra; Marcello Gambacorta; Sergio Cortelazzo; Alessandra Tucci; Marco Ungari; Achille Ambrosetti; Fabio Menestrina; Lorella Orsucci; Domenico Novero; Alessandro Pulsoni; Maurizio Frezzato; Gianluca Gaidano; Daniele Vallisa; Viviana Minardi; Claudio Tripodo; Vincenzo Callea; Luca Baldini; Francesco Merli; Massimo Federico; Vito Franco; Emilio Iannitto
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

8.  Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier.

Authors:  Katsuya Fujimoto; Tomoyuki Endo; Mitsufumi Nishio; Masato Obara; Keisuke Yamaguchi; Yukari Takeda; Hideki Goto; Ikumi Kasahara; Norihiro Sato; Takao Koike
Journal:  Int J Hematol       Date:  2009-10-06       Impact factor: 2.490

9.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

10.  High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.

Authors:  Shuhua Yi; Dehui Zou; Chengwen Li; Shizhen Zhong; Weiwei Chen; Zengjun Li; Wenjie Xiong; Wei Liu; Enbin Liu; Rui Cui; Kun Ru; Peihong Zhang; Yan Xu; Gang An; Rui Lv; Junyuan Qi; Jianxiang Wang; Tao Cheng; Lugui Qiu
Journal:  Oncotarget       Date:  2015-12-08
View more
  3 in total

Review 1.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

2.  Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.

Authors:  Jun Wang; Yuting Yan; Wenjie Xiong; Ge Song; Yi Wang; Jiawei Zhao; Yujiao Jia; Chengwen Li; Zhen Yu; Ying Yu; Jiawen Chen; Yang Jiao; Tingyu Wang; Rui Lyu; Qinghua Li; Yueshen Ma; Wei Liu; Dehui Zou; Gang An; Qi Sun; Huijun Wang; Zhijian Xiao; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Blood Adv       Date:  2022-07-12

3.  Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort Study

Authors:  Müfide Okay; Tuncay Aslan; Evren Özdemir; Ayşegül Üner; Arzu Sağlam; Elif Güngör; Ayşe Uysal; Nevin Alayvaz Aslan; Esra Yıldızhan; Abdullah Ağıt; Mehmet Sinan Dal; Serdal Korkmaz; Sinem Namdaroğlu; Serdar Sivgin; Gülsüm Akgün Çağlıyan; Sinan Demircioğlu; İbrahim Barışta; Esra Özhamam; Filiz Vural; Bülent Eser; Gülsüm Özet; Rahşan Yıldırım; Mehmet Hilmi Doğu; İlhami Berber; Mehmet Ali Erkurt; Ümit Yavuz Malkan; Fevzi Altuntaş; Yahya Büyükaşık
Journal:  Turk J Haematol       Date:  2019-10-21       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.